Bristol Myers Squibb (BMY)
(Delayed Data from NYSE)
$53.76 USD
+0.86 (1.63%)
Updated Oct 2, 2024 04:00 PM ET
After-Market: $53.98 +0.22 (0.41%) 7:58 PM ET
3-Hold of 5 3
B Value B Growth C Momentum B VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$53.76 USD
+0.86 (1.63%)
Updated Oct 2, 2024 04:00 PM ET
After-Market: $53.98 +0.22 (0.41%) 7:58 PM ET
3-Hold of 5 3
B Value B Growth C Momentum B VGM
Zacks News
Exelixis's Cabometyx Positive for First-Line Kidney Cancer
by Zacks Equity Research
Exelixis, Inc. (EXEL) announced results from an analysis of the data from the phase II trial, CABOSUN evaluating Cabometyx to Sutent for kidney cancer.
Gilead's (GILD) HBV Drug Vemlidy Receives Approval in Canada
by Zacks Equity Research
Health Canada granted a Notice of Compliance (NOC) for Vemlidy 25mg tablets, a once-daily treatment for adults with chronic HBV infection with compensated liver disease.
Bristol-Myers Opdivo Positive in Phase II Study CheckMate-205
by Zacks Equity Research
Bristol-Myers Squibb Company (BMY) announced an extended follow-up data on immuno-oncology drug Opdivo.
J&J Immunotherapy Darzalex Ok'd for Expanded Combination Use
by Zacks Equity Research
Johnson & Johnson (JNJ) announced that its immunotherapy, Darzalex has been approved for use in combination with Celgene Corporation's (CELG) multiple myeloma drug Pomalyst (pomalidomide) and dexamethasone.
Pharma Stock Roundup: J&J, Lilly Present Data, Merck Keytruda Study Enrolment Paused
by Arpita Dutt
Merck (MRK) paused patient enrolment in a couple of studies being conducted with its anti-PD-1 therapy, Keytruda.
Exelixis Initiates Cabozantinib-Tecentriq Combination Trial
by Zacks Equity Research
Exelixis, Inc. (EXEL) announced that it initiated the dose-escalation stage of a phase Ib trial of cabozantinib in combination with Roche's (RHHBY) Tecentriq.
Novartis, Bristol-Myers Collaborate for Opdivo Combination
by Zacks Equity Research
Novartis AG (NVS) and Bristol-Myers Squibb Company (BMY) collaborate for Opdivo combination therapies.
Incyte Provides Updated Data on Cancer Combination Therapies
by Zacks Equity Research
Incyte along with partner Bristol-Myers Squibb announced updated data from phase I/II study, ECHO-204, evaluating epacadostat in combination with Opdivo for the treatment of squamous cell carcinoma of the head and neck and melanoma.
Bristol-Myers Presents Data on Immuno-Oncology Drug Opdivo
by Zacks Equity Research
Bristol-Myers BMY announced that the EC has approved immuno-oncology drug Opdivo for the treatment of locally advanced unresectable or metastatic urothelial carcinoma (mUC) in adults after failure of prior platinum-containing therapy.
Amgen (AMGN) Presents Positive Clinical Data on Cancer Drugs
by Zacks Equity Research
Amgen, Inc. (AMGN) presented encouraging results from a phase III study, evaluating its marketed drug Xgeva (denosumab) for an expanded indication at the American Society of Clinical Oncology.
Incyte Announces Data on Enzyme Inhibitor with Keytruda
by Zacks Equity Research
Incyte Corporation (INCY) and Merck & Co. (MRK) announced an updated data from the advanced non-small cell lung cancer patient cohort of the ongoing phase I/II ECHO-202 study.
Pfizer's Kidney Cancer Drug Gets Acceptance in the U.S. & EU
by Zacks Equity Research
Pfizer Inc. (PFE) announced encouraging news with the FDA and the European Medicines Agency (EMA) accepting the company's regulatory submission for label expansion of its cancer drug, Sutent (sunitinib).
Pharma Stock Roundup: Positive Data from Lilly & Teva, BMY's Deals & More
by Arpita Dutt
Lilly (LLY) posted positive data on Cyramza while Teva's migraine drug delivered positive results in a late-stage study.
Why Is Bristol-Myers (BMY) Down 3.1% Since the Last Earnings Report?
by Zacks Equity Research
Bristol-Myers (BMY) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Bristol-Myers Partners Array to Investigate Cancer Candidate
by Zacks Equity Research
Bristol-Myers Squibb Company (BMY) and Array BioPharma (ARRY) entered into a clinical research collaboration to investigate the safety, tolerability and efficacy of Array's binimetinib in combination with the former's Opdivo and Opdivo + Yervoy regimen.
Merck (MRK) Buys Rights to Anti-tau Antibody for Alzheimer
by Zacks Equity Research
Merck & CO, Inc. (MRK) announced that it has bought exclusive worldwide license from Teijin Pharma for the development, manufacture and commercialization of an investigational preclinical anti-tau antibody.
Celldex's Immuno-Oncology Pipeline Continues to Impress
by Zacks Equity Research
On May 25, we issued an updated research report on Hampton, NJ-based Celldex Therapeutics, Inc. (CLDX).
Pharma Stock Roundup: Label Expansion for Merck Drug, Aerie Up On Eye Data
by Arpita Dutt
Merck (MRK) got another approval for Keytruda while Aerie shot up on positive data.
Bristol-Myers' Opdivo Gets Priority Review for Liver Cancer
by Zacks Equity Research
Bristol-Myers Squibb Company (BMY) announced that the FDA has accepted and granted a priority review designation to the supplemental Biologics License Application for the label expansion of Opdivo to patients with hepatocellular carcinoma (HCC).
Merck KGaA (MKGAF) Q1 Earnings Fall Y/Y, Revenues Increase
by Zacks Equity Research
Merck KGaA (MKGAF) reported first-quarter 2017 earnings of $1.28 per American Depositary Share, 14.7% lower than the year-ago figure of $1.50.
Pharma Stock Roundup: J&J's Pharma Pipeline Update, Shire's HAE Data & More
by Arpita Dutt
This week, industry bellwether J&J (JNJ) provided a look at its pharma pipeline while Shire was up on HAE data.
New Research Reports for Britol-Myers, Pricline & Phillips 66
by Sheraz Mian
Today's Research Daily features new research reports on 16 major stocks, including Bristol-Myers (BMY), Priceline (PCLN) and Phillips 66 (PSX).
Incyte (INCY) Announces Positive Data on Enzyme Inhibitor
by Zacks Equity Research
Incyte Corporation (INCY) recently announced that new data was published from the ongoing trial, ECHO-202 online by the American Society of Clinical Oncology (ASCO).
Biogen (BIIB) Buys Stroke Candidate Cirara for $120M
by Zacks Equity Research
Biogen Inc. (BIIB) announced the acquisition of Remedy Pharmaceuticals' phase III candidate, Cirara for the treatment of large hemispheric stroke (LHI).
AstraZeneca Imfinzi Positive in Phase III Lung Cancer Study
by Zacks Equity Research
AstraZeneca PLC (AZN) recently announced positive data from a phase III PACIFIC study evaluating its oncology candidate, Imfinzi (durvalumab).